MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Study acronym: MOONRAY-01
StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Primary and study completion moved earlier from Mar 2029 to Mar 2028
    • Eligibility criteria expanded, about 11 words
    • Site details revised at 52 of 52 sites
  2. Study sites revised (52)v23
  3. Study sites revised (52)v22
  4. Site details revised at 1 of 52 sitesv21
  5. Site details revised at 1 of 52 sitesv20
Show 18 earlier versionsHide 18 earlier versions
  1. Enrollment target: 570 to 630v19
  2. Site details revised at 3 of 52 sitesv18
  3. Site details revised at 1 of 52 sitesv17
  4. Site details revised at 1 of 52 sitesv16
  5. Site details revised at 6 of 52 sitesv15
  6. Site details revised at 3 of 52 sitesv14
  7. Site contacts updated at 52 of 52 sitesv13
  8. Enrollment target: 540 to 570
    • Site contacts updated at 52 of 52 sites
    v12
  9. Study sites: 48 to 52v11
  10. Study sites: 46 to 48v10
  11. Enrollment target: 530 to 540
    • Study sites: 45 to 46
    • Study arms: 2 to 3
    • Study title expanded, about 1 word
    v9
  12. Re-verified, no change to tracked fieldsv8
  13. Study sites: 43 to 45v7
  14. Study sites: 8 to 43v6
  15. Study sites: 5 to 8v5
  16. Study sites: 41 to 5
    • Collaborators shortened, about 3 words
    v4
  17. Study sites: 2 to 41v3
  18. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 2
    • Primary and study completion dates: Mar 31, 2029 to Mar 2029
    • Start date changed from estimate of Sep 15, 2024 to Sep 12, 2024
    • Eligibility criteria expanded, about 1 word
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
365 trials monitored
See 16 trials at risk
Lung Cancer
4,803 trials monitored
See 272 trials at risk
Colorectal Cancer
3,410 trials monitored
See 164 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,087 trials monitored
See 179 trials at risk
and 1 more disease
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Trial Details
NCT Number NCT06586515
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Related terms Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Enrollment 630 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov